996 related articles for article (PubMed ID: 27539689)
1. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
Sherwood MW; Cyr DD; Jones WS; Becker RC; Berkowitz SD; Washam JB; Breithardt G; Fox KA; Halperin JL; Hankey GJ; Singer DE; Piccini JP; Nessel CC; Mahaffey KW; Patel MR
JACC Cardiovasc Interv; 2016 Aug; 9(16):1694-702. PubMed ID: 27539689
[TBL] [Abstract][Full Text] [Related]
2. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
[TBL] [Abstract][Full Text] [Related]
3. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
[TBL] [Abstract][Full Text] [Related]
4. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).
Sherwood MW; Douketis JD; Patel MR; Piccini JP; Hellkamp AS; Lokhnygina Y; Spyropoulos AC; Hankey GJ; Singer DE; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Becker RC;
Circulation; 2014 May; 129(18):1850-9. PubMed ID: 24552831
[TBL] [Abstract][Full Text] [Related]
7. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).
Gibson CM; Mehran R; Bode C; Halperin J; Verheugt F; Wildgoose P; van Eickels M; Lip GY; Cohen M; Husted S; Peterson E; Fox K
Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853
[TBL] [Abstract][Full Text] [Related]
8. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.
Gibson CM; Mehran R; Bode C; Halperin J; Verheugt FW; Wildgoose P; Birmingham M; Ianus J; Burton P; van Eickels M; Korjian S; Daaboul Y; Lip GY; Cohen M; Husted S; Peterson ED; Fox KA
N Engl J Med; 2016 Dec; 375(25):2423-2434. PubMed ID: 27959713
[TBL] [Abstract][Full Text] [Related]
9. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
Desai A; Escamilla-Ocanas C; Dilip D; Saber H; Damani R
J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105654. PubMed ID: 33578352
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
[TBL] [Abstract][Full Text] [Related]
12. Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Chen ST; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
Am J Cardiol; 2017 Nov; 120(10):1837-1840. PubMed ID: 28886856
[TBL] [Abstract][Full Text] [Related]
13. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
Pokorney SD; Piccini JP; Stevens SR; Patel MR; Pieper KS; Halperin JL; Breithardt G; Singer DE; Hankey GJ; Hacke W; Becker RC; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; ;
J Am Heart Assoc; 2016 Mar; 5(3):e002197. PubMed ID: 26955859
[TBL] [Abstract][Full Text] [Related]
14. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.
Cannon CP; Gropper S; Bhatt DL; Ellis SG; Kimura T; Lip GY; Steg PG; Ten Berg JM; Manassie J; Kreuzer J; Blatchford J; Massaro JM; Brueckmann M; Ferreiros Ripoll E; Oldgren J; Hohnloser SH;
Clin Cardiol; 2016 Oct; 39(10):555-564. PubMed ID: 27565018
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Choi HI; Ahn JM; Kang SH; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
JACC Cardiovasc Interv; 2017 Jun; 10(11):1075-1085. PubMed ID: 28527773
[TBL] [Abstract][Full Text] [Related]
16. Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention.
Olivier CB; Fan J; Askari M; Mahaffey KW; Heidenreich PA; Perino AC; Leef GC; Ho PM; Harrington RA; Turakhia MP
Circ Cardiovasc Interv; 2019 Aug; 12(8):e007604. PubMed ID: 31416357
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies.
Bavishi C; Koulova A; Bangalore S; Sawant A; Chatterjee S; Ather S; Valencia J; Sarafoff N; Rubboli A; Airaksinen JK; Lip GY; Tamis-Holland JE
Catheter Cardiovasc Interv; 2016 Jul; 88(1):E12-22. PubMed ID: 26354765
[TBL] [Abstract][Full Text] [Related]
18. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
Kopin D; Jones WS; Sherwood MW; Wojdyla DM; Wallentin L; Lewis BS; Verheugt FWA; Vinereanu D; Bahit MC; Halvorsen S; Huber K; Parkhomenko A; Granger CB; Lopes RD; Alexander JH
Am Heart J; 2018 Mar; 197():133-141. PubMed ID: 29447773
[TBL] [Abstract][Full Text] [Related]
19. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial.
Sambola A; Montoro JB; Del Blanco BG; Llavero N; Barrabés JA; Alfonso F; Bueno H; Cequier A; Serra A; Zueco J; Sabaté M; Rodríguez-Leor O; García-Dorado D
Am Heart J; 2013 Oct; 166(4):669-75. PubMed ID: 24093846
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).
Goodman SG; Wojdyla DM; Piccini JP; White HD; Paolini JF; Nessel CC; Berkowitz SD; Mahaffey KW; Patel MR; Sherwood MW; Becker RC; Halperin JL; Hacke W; Singer DE; Hankey GJ; Breithardt G; Fox KA; Califf RM;
J Am Coll Cardiol; 2014 Mar; 63(9):891-900. PubMed ID: 24315894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
